Over the past weeks, I ran multiple versions of the same systematic equity strategy on the DJ30 universe.
At first glance, some versions looked extraordinary:
– Sharpe above 2.4
– Calmar above 3
– Max drawdown below -6%
On paper, they were beautiful.
But then the real question emerged: Can this survive at $1–5 billion AUM?
That question changes everything.
When you move from “a few hundred million” to “billions,” the objective shifts:
It is no longer about maximizing Sharpe. It is about maximizing survivability under scale.
Here is what becomes critical at that level:
– Average daily turnover
– Tail turnover (days with extreme rebalancing)
– Cost amplification under stress
– Liquidity concentration per name
A strategy with 7% daily turnover may look superior in backtests. But at $5bn, that is $350m traded per day.
Market impact becomes nonlinear. Alpha evaporates.
So I intentionally moved to a lower-intensity structure:
• ~2.4% average daily turnover
• ~1.3 bps annual execution cost
• Minimal stress amplification
• Very thin cost tails
Sharpe dropped from >2.3 to ~1.8.
That trade-off is intentional.
Because at institutional scale: A robust Sharpe 1.8 that survives size is superior to a fragile Sharpe 2.5 that collapses under impact.
The uncomfortable truth is this: Most strategies are designed to look good at small size. Very few are engineered to survive billions.
When your ambition changes, your design philosophy must change.
At billion-dollar scale, you optimize for:
• Liquidity governance
• Turnover discipline
• Impact containment
• Structural robustness
Not just return metrics. Performance attracts capital. Capacity keeps it.
And if the goal is to build a flagship institutional strategy, capacity discipline must come before cosmetic Sharpe optimization.
That is the real allocator mindset shift.
Leave a Reply